In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Cardiff Oncology (CRDF – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.62.
According to TipRanks, Catanzaro is a 3-star analyst with an average return of 0.9% and a 32.40% success rate. Catanzaro covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Cardiff Oncology, and Iovance Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cardiff Oncology with a $7.33 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.79 and a one-year low of $1.20. Currently, Cardiff Oncology has an average volume of 639.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cardiff Oncology (CRDF) Company Description:
Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
Read More on CRDF:
- Cardiff Oncology price target lowered to $12 from $13 at H.C. Wainwright
- Cardiff Oncology reports Q2 EPS (25c), consensus (26c)
- Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
- Cardiff Oncology (NASDAQ:CRDF) Rockets Upward With New Support, Cancer Treatments
- Cardiff Oncology price target lowered to $13 from $14 at H.C. Wainwright
